The European Centre for Disease Prevention and Control has reported record levels of bacterial sexually transmitted infections across Europe, with 106,331 gonorrhoea cases, 45,577 syphilis cases, 213,443 chlamydia cases and 3,490 lymphogranuloma venereum cases recorded in 2024. The findings place Europe’s sexual health infrastructure under renewed pressure, especially as gonorrhoea cases have risen 303% since 2015 and congenital syphilis cases have nearly doubled year on year.

Why Europe’s STI surge is becoming a diagnostics and access problem rather than only a behaviour story

The latest European STI data matters because the increase is not confined to one pathogen, one age group or one explanation. Gonorrhoea, chlamydia and lymphogranuloma venereum are all moving through a healthcare environment where testing access, sexual health literacy, surveillance quality and treatment pathways vary materially across countries. That makes the 2024 data less of a simple epidemiological spike and more of a warning that sexual health systems are struggling to match the pace and diversity of transmission.

The confirmed development is clear. Europe is seeing record or near-record levels of several bacterial sexually transmitted infections. The clinical context is equally serious because untreated sexually transmitted infections can lead to complications such as infertility, chronic pelvic pain, adverse pregnancy outcomes and, in the case of syphilis, cardiovascular or neurological disease. The unresolved question is whether the reported rise reflects improved testing and surveillance, a genuine increase in transmission, or a difficult mix of both. That distinction matters because a testing-led rise requires one policy response, while a transmission-led rise demands broader prevention, partner notification and behavioural interventions.

For diagnostics companies, public health laboratories and sexual health clinics, the signal is obvious. Demand for accessible, accurate and rapid testing is likely to keep rising, but the market opportunity is tied to public funding, reimbursement structures and clinic capacity. A test that performs well in a laboratory is only useful at scale if people can access it, clinicians can act on the result, and health systems can use the data to interrupt transmission chains. That is where Europe’s STI surge becomes an adoption problem, not just a technology problem.

What the rise in gonorrhoea cases reveals about antimicrobial resistance risk in Europe

Gonorrhoea is the most strategically worrying part of the STI picture because it combines rising incidence with a long-standing antimicrobial resistance threat. The ECDC reported 106,331 gonorrhoea cases in 2024, a 303% increase since 2015, which makes the scale of transmission far larger than a decade ago. The immediate clinical issue is diagnosis and treatment, but the wider industry issue is whether current antibiotic options can remain effective if case numbers continue to climb.

The commercial and regulatory context is uncomfortable. Gonorrhoea has repeatedly shown an ability to develop resistance to multiple antibiotic classes, which means public health authorities cannot treat rising case numbers as a routine volume issue. Higher incidence increases the number of treatment events, and more treatment events can increase selective pressure if antibiotic stewardship is weak or if follow-up is inconsistent. That does not mean Europe is facing imminent treatment failure across the board, but it does mean surveillance quality and treatment guideline compliance become more important as case volumes rise.

The blind spot is product development. Antibiotic innovation remains commercially difficult because stewardship principles encourage careful use, while developers need a return on investment. Gonorrhoea therefore sits in a difficult category: clinically important, epidemiologically expanding and commercially awkward. If Europe wants durable treatment capacity, the response cannot rely only on existing antibiotics. It will also need better point-of-care diagnostics, antimicrobial susceptibility monitoring, partner management and possibly new prevention tools over time.

Why syphilis and congenital syphilis are raising the stakes for prenatal screening

Syphilis is particularly concerning because its public health consequences extend beyond adult transmission. The ECDC reported that syphilis cases more than doubled between 2015 and 2024 to 45,577 cases, while congenital syphilis cases nearly doubled from 78 in 2023 to 140 in 2024. That increase shifts the conversation from sexual health clinics alone to antenatal care, maternal health services and health equity.

The confirmed development is not simply that more syphilis cases are being detected. It is that Europe is also seeing a rise in congenital syphilis, which is largely preventable when screening, treatment and follow-up work properly. The clinical context is severe because congenital syphilis can cause miscarriage, stillbirth, neonatal death or long-term complications in infants. The unresolved question is where exactly the system is failing: late access to prenatal care, missed screening opportunities, delayed treatment, reinfection, partner treatment gaps or uneven coverage among vulnerable populations.

For healthcare systems, the answer is unlikely to be a single intervention. Prenatal screening may need stronger standardisation, but screening alone is not enough if treatment access, case management and contact tracing remain weak. For diagnostics manufacturers, this creates demand for reliable syphilis testing across clinical settings, including antenatal workflows. However, the bigger constraint may be implementation rather than assay availability. Europe does not lack knowledge about syphilis prevention. The problem is ensuring that every pregnant person at risk is reached early enough, tested accurately and treated promptly.

How chlamydia’s high case burden complicates Europe’s STI response

Chlamydia remains the most frequently reported sexually transmitted infection in the ECDC dataset, with 213,443 reported cases in 2024. Its role in the STI landscape is different from gonorrhoea and syphilis because chlamydia is often asymptomatic, can be underdiagnosed and can quietly drive reproductive health complications when testing coverage is weak.

The confirmed development is that chlamydia continues to account for the largest reported case volume. The clinical context is that many infections do not produce obvious symptoms, making opportunistic testing, screening programmes and digital access pathways especially important. The risk is that health systems may focus attention on the sharper percentage increases in gonorrhoea and syphilis while underestimating the persistent burden of chlamydia, especially among younger adults and groups with lower access to routine sexual health services.

For industry, chlamydia remains central to multiplex testing strategies. Combined assays for chlamydia and gonorrhoea are already common in many settings, and the logic for integrated STI panels strengthens when multiple infections are rising or circulating simultaneously. However, broader testing panels can create reimbursement and workflow questions. More testing may detect more infections, but health systems must also absorb counselling, treatment, partner notification and repeat testing. A positive result is not the end of the pathway. It is the beginning of a care process that many systems are already struggling to support.

Why prevention gaps could become the biggest obstacle to controlling STI transmission

Testing is essential, but testing alone cannot control rising STI transmission. The ECDC has already flagged gaps in prevention policies, testing access and data quality across Europe’s response to sexually transmitted infections. That makes prevention the most difficult part of the current challenge because it requires behaviour change, public trust, accessible services and sustained public health funding.

The confirmed development is that Europe has national strategies in many places, but still faces barriers in prevention and testing. The broader context is that sexual health prevention is often underfunded compared with higher-profile infectious disease programmes. It may also be politically sensitive, unevenly implemented and difficult to measure in short budget cycles. The unresolved question is whether governments will treat the new data as a trigger for structural investment or as another report that produces short-term messaging without durable system change.

The prevention problem also affects industry strategy. Diagnostics and therapeutics can help manage infections, but they do not automatically reduce incidence unless paired with outreach, education, condom access, partner services and targeted screening. Public health leaders may increasingly look for integrated models that combine laboratory testing, home sampling, digital result delivery and linkage to treatment. That could create a more attractive market for service-enabled diagnostics, but only if reimbursement and public procurement frameworks evolve.

Why lymphogranuloma venereum deserves more attention despite lower headline numbers

Lymphogranuloma venereum recorded 3,490 reported cases in 2024, far below chlamydia, gonorrhoea or syphilis in absolute terms. Yet the infection matters because it highlights how STI surveillance must track not only the biggest numbers but also infections that may cluster in specific networks or require more specialised clinical recognition.

The confirmed development is ongoing transmission. The clinical context is that lymphogranuloma venereum is caused by specific strains of Chlamydia trachomatis and can present with more invasive disease than common urogenital chlamydia infections. The risk is that lower awareness, variable testing protocols and limited routine typing may cause under-recognition in some settings. That matters because an infection can be epidemiologically significant even when the headline number is smaller.

For diagnostics and laboratory networks, lymphogranuloma venereum raises the value of more granular testing strategies in higher-risk populations. Routine chlamydia testing may detect Chlamydia trachomatis, but additional differentiation may be needed when clinical presentation or epidemiological context suggests lymphogranuloma venereum. The challenge is balancing precision with cost. Public health systems must decide when targeted testing is clinically justified and when broader surveillance is needed to understand transmission patterns.

What clinicians, regulators and industry observers should watch next

The next phase will be defined by whether Europe can convert surveillance data into operational change. Clinicians will watch for updated testing guidance, expanded screening recommendations and more consistent partner notification pathways. Public health agencies will watch whether countries with higher case burdens can improve access to sexual health services without overwhelming clinics. Diagnostics companies will watch procurement priorities, especially around multiplex panels, home collection models and faster turnaround solutions.

Regulatory watchers will also focus on antimicrobial resistance management, particularly in gonorrhoea. Rising incidence makes resistance surveillance more urgent, and resistance surveillance depends on laboratory capacity, data sharing and consistent clinical sampling. If resistance concerns intensify, the field could see greater demand for diagnostics that identify not only the pathogen but also resistance markers. That would represent a shift from simple detection toward treatment-guiding diagnostics.

The adoption risk is that Europe may diagnose more infections without building enough care capacity around the result. More testing can create the impression of progress, but untreated partners, delayed treatment, limited counselling and weak follow-up can keep transmission chains alive. The sharper opportunity is to build STI care as a connected system, not a series of disconnected tests and prescriptions. That is less glamorous than a new platform announcement, but it is where the public health payoff sits.

Why this STI surge should matter to the pharma and diagnostics sector

Europe’s STI surge is a reminder that infectious disease markets do not disappear when emergency headlines fade. They shift into chronic public health infrastructure problems, where diagnostics, antibiotics, surveillance, digital access and prevention all interact. For pharma and diagnostics stakeholders, the STI field may look mature, but the current data suggest it is becoming strategically relevant again.

The investment case is not simple. Diagnostics demand may rise, but public budgets can be tight. Antibiotic need is clear, but commercial incentives remain weak. Prevention tools are essential, but behaviour change is difficult to scale. Still, the direction of travel is hard to ignore. A Europe-wide rise in gonorrhoea, syphilis, chlamydia and lymphogranuloma venereum creates a larger addressable need for integrated sexual health services, better laboratory infrastructure and more resilient treatment strategies.

The most important conclusion is that Europe’s STI problem is no longer just about awareness campaigns. It is about whether health systems can detect infections earlier, treat them reliably, prevent reinfection, monitor resistance and protect vulnerable groups, including pregnant women and newborns. That is a systems challenge. And in healthcare, systems challenges are exactly where the next wave of diagnostics, public health procurement and treatment innovation usually begins.

  antimicrobial resistance, chlamydia, Diagnostics, European Centre for Disease Prevention and Control, gonorrhoea, lymphogranuloma venereum, prenatal screening, public health, sexually transmitted infections, syphilis